

Eczema Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

Market Report | 2023-12-04 | 255 pages | Infinium Global Research and Consulting Solutions

AVAILABLE LICENSES:

- 1-5 User \$4795.00
- Enterprise \$7195.00

Report description:

The report on the global eczema therapeutics market provides qualitative and quantitative analysis for the period from 2021-2030. The global eczema therapeutics market was valued at USD 20.22 billion in 2022 and is expected to reach USD 43.41 billion in 2030, with a CAGR of 10.12% during the forecast period 2023-2030. The study on eczema therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030. The report on eczema therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global eczema therapeutics market over the period of 2021-2030. Moreover, the report is a collective presentation of primary and secondary research findings. Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global eczema therapeutics market over the period of 2021-2030. Further, IGR-Growth Matrix given in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

- The increasing incidence of eczema is poised to significantly boost the growth of the eczema therapeutics market.
- Increasing research and development activities for development of novel treatments for eczema are anticipated to fuel the growth of the market.

2) Restraints

- Delays in product approvals from the regulatory authorities for the treatment of eczema may restrain the market growth.

3) Opportunities

- The growing availability of sound reimbursement policies for eczema treatment coupled with highly developed medical infrastructure will considerably grow opportunities for the eczema therapeutics market in the upcoming future.

Research Methodology

A) Primary Research

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

1. Key Opinion Leaders associated with Infinium Global Research
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Our primary research respondents typically include

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global eczema therapeutics market is segmented on the basis of drug class, disease indication, and distribution channel.

The Global Eczema Therapeutics Market by Drug Class

- Calcineurin Inhibitors
- PDE4 Inhibitors
- Corticosteroids
- Others

The Global Eczema Therapeutics Market by Disease Indication

- Atopic Dermatitis
- Contact Dermatitis

The Global Eczema Therapeutics Market by Distribution Channel

- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy

Company Profiles

The companies covered in the report include

- Pfizer Inc.
- AstraZeneca
- GSK plc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Meda AB (acquired by Mylan)
- Sanofi
- Encore Dermatology
- AbbVie Inc.
- Astellas Pharma Inc.
- Novartis AG
- Regeneron Pharmaceuticals Inc.

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the eczema therapeutics market.
2. Complete coverage of all the segments in the eczema therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global eczema therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Table of Contents:

Table of Content

Chapter 1. Preface

- 1.1. Report Description
- 1.2. Research Methods
- 1.3. Research Approaches

Chapter 2. Executive Summary

- 2.1. Eczema Therapeutics Market Highlights
- 2.2. Eczema Therapeutics Market Projection
- 2.3. Eczema Therapeutics Market Regional Highlights

Chapter 3. Global Eczema Therapeutics Market Overview

- 3.1. Introduction
- 3.2. Market Dynamics
 - 3.2.1. Drivers
 - 3.2.2. Restraints
 - 3.2.3. Opportunities
- 3.3. Porter's Five Forces Analysis
- 3.4. IGR-Growth Matrix Analysis
 - 3.4.1. IGR-Growth Matrix Analysis by Drug Class
 - 3.4.2. IGR-Growth Matrix Analysis by Disease Indication
 - 3.4.3. IGR-Growth Matrix Analysis by Distribution Channel
 - 3.4.4. IGR-Growth Matrix Analysis by Region
- 3.5. Value Chain Analysis of Eczema Therapeutics Market

Chapter 4. Eczema Therapeutics Market Macro Indicator Analysis

Chapter 5. Company Profiles and Competitive Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1. Competitive Landscape in the Global Eczema Therapeutics Market
- 5.2. Companies Profiles
 - 5.2.1. Pfizer Inc.
 - 5.2.2. AstraZeneca
 - 5.2.3. GSK plc.
 - 5.2.4. Meda AB (acquired by Mylan)
 - 5.2.5. Sanofi
 - 5.2.6. Encore Dermatology
 - 5.2.7. AbbVie Inc.
 - 5.2.8. Astellas Pharma Inc.
 - 5.2.9. Novartis AG
 - 5.2.10. Regeneron Pharmaceuticals Inc.

Chapter 6. Global Eczema Therapeutics Market by Drug Class

- 6.1. Calcineurin Inhibitors
- 6.2. PDE4 Inhibitors
- 6.3. Corticosteroids
- 6.4. Others

Chapter 7. Global Eczema Therapeutics Market by Disease Indication

- 7.1. Atopic Dermatitis
- 7.2. Contact Dermatitis

Chapter 8. Global Eczema Therapeutics Market by Distribution Channel

- 8.1. Hospital Pharmacy
- 8.2. Retail Pharmacy
- 8.3. Online Pharmacy

Chapter 9. Global Eczema Therapeutics Market by Region 2023-2030

- 9.1. North America
 - 9.1.1. North America Eczema Therapeutics Market by Drug Class
 - 9.1.2. North America Eczema Therapeutics Market by Disease Indication
 - 9.1.3. North America Eczema Therapeutics Market by Distribution Channel
 - 9.1.4. North America Eczema Therapeutics Market by Country
 - 9.1.4.1. The U.S. Eczema Therapeutics Market
 - 9.1.4.1.1. The U.S. Eczema Therapeutics Market by Drug Class
 - 9.1.4.1.2. The U.S. Eczema Therapeutics Market by Disease Indication
 - 9.1.4.1.3. The U.S. Eczema Therapeutics Market by Distribution Channel
 - 9.1.4.2. Canada Eczema Therapeutics Market
 - 9.1.4.2.1. Canada Eczema Therapeutics Market by Drug Class
 - 9.1.4.2.2. Canada Eczema Therapeutics Market by Disease Indication
 - 9.1.4.2.3. Canada Eczema Therapeutics Market by Distribution Channel
 - 9.1.4.3. Mexico Eczema Therapeutics Market
 - 9.1.4.3.1. Mexico Eczema Therapeutics Market by Drug Class
 - 9.1.4.3.2. Mexico Eczema Therapeutics Market by Disease Indication
 - 9.1.4.3.3. Mexico Eczema Therapeutics Market by Distribution Channel
 - 9.2. Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.1.□Europe Eczema Therapeutics Market by Drug Class
- 9.2.2.□Europe Eczema Therapeutics Market by Disease Indication
- 9.2.3.□Europe Eczema Therapeutics Market by Distribution Channel
- 9.2.4.□Europe Eczema Therapeutics Market by Country
- 9.2.4.1.□Germany Eczema Therapeutics Market
- 9.2.4.1.1.□Germany Eczema Therapeutics Market by Drug Class
- 9.2.4.1.2.□Germany Eczema Therapeutics Market by Disease Indication
- 9.2.4.1.3.□Germany Eczema Therapeutics Market by Distribution Channel
- 9.2.4.2.□United Kingdom Eczema Therapeutics Market
- 9.2.4.2.1.□United Kingdom Eczema Therapeutics Market by Drug Class
- 9.2.4.2.2.□United Kingdom Eczema Therapeutics Market by Disease Indication
- 9.2.4.2.3.□United Kingdom Eczema Therapeutics Market by Distribution Channel
- 9.2.4.3.□France Eczema Therapeutics Market
- 9.2.4.3.1.□France Eczema Therapeutics Market by Drug Class
- 9.2.4.3.2.□France Eczema Therapeutics Market by Disease Indication
- 9.2.4.3.3.□France Eczema Therapeutics Market by Distribution Channel
- 9.2.4.4.□Italy Eczema Therapeutics Market
- 9.2.4.4.1.□Italy Eczema Therapeutics Market by Drug Class
- 9.2.4.4.2.□Italy Eczema Therapeutics Market by Disease Indication
- 9.2.4.4.3.□Italy Eczema Therapeutics Market by Distribution Channel
- 9.2.4.5.□Rest of Europe Eczema Therapeutics Market
- 9.2.4.5.1.□Rest of Europe Eczema Therapeutics Market by Drug Class
- 9.2.4.5.2.□Rest of Europe Eczema Therapeutics Market by Disease Indication
- 9.2.4.5.3.□Rest of Europe Eczema Therapeutics Market by Distribution Channel
- 9.3.□Asia Pacific
- 9.3.1.□Asia Pacific Eczema Therapeutics Market by Drug Class
- 9.3.2.□Asia Pacific Eczema Therapeutics Market by Disease Indication
- 9.3.3.□Asia Pacific Eczema Therapeutics Market by Distribution Channel
- 9.3.4.□Asia Pacific Eczema Therapeutics Market by Country
- 9.3.4.1.□China Eczema Therapeutics Market
- 9.3.4.1.1.□China Eczema Therapeutics Market by Drug Class
- 9.3.4.1.2.□China Eczema Therapeutics Market by Disease Indication
- 9.3.4.1.3.□China Eczema Therapeutics Market by Distribution Channel
- 9.3.4.2.□Japan Eczema Therapeutics Market
- 9.3.4.2.1.□Japan Eczema Therapeutics Market by Drug Class
- 9.3.4.2.2.□Japan Eczema Therapeutics Market by Disease Indication
- 9.3.4.2.3.□Japan Eczema Therapeutics Market by Distribution Channel
- 9.3.4.3.□India Eczema Therapeutics Market
- 9.3.4.3.1.□India Eczema Therapeutics Market by Drug Class
- 9.3.4.3.2.□India Eczema Therapeutics Market by Disease Indication
- 9.3.4.3.3.□India Eczema Therapeutics Market by Distribution Channel
- 9.3.4.4.□South Korea Eczema Therapeutics Market
- 9.3.4.4.1.□South Korea Eczema Therapeutics Market by Drug Class
- 9.3.4.4.2.□South Korea Eczema Therapeutics Market by Disease Indication
- 9.3.4.4.3.□South Korea Eczema Therapeutics Market by Distribution Channel
- 9.3.4.5.□Australia Eczema Therapeutics Market
- 9.3.4.5.1.□Australia Eczema Therapeutics Market by Drug Class

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.4.5.2. □Australia Eczema Therapeutics Market by Disease Indication
- 9.3.4.5.3. □Australia Eczema Therapeutics Market by Distribution Channel
- 9.3.4.6. □Rest of Asia-Pacific Eczema Therapeutics Market
- 9.3.4.6.1. □Rest of Asia-Pacific Eczema Therapeutics Market by Drug Class
- 9.3.4.6.2. □Rest of Asia-Pacific Eczema Therapeutics Market by Disease Indication
- 9.3.4.6.3. □Rest of Asia-Pacific Eczema Therapeutics Market by Distribution Channel
- 9.4. □RoW
- 9.4.1. □RoW Eczema Therapeutics Market by Drug Class
- 9.4.2. □RoW Eczema Therapeutics Market by Disease Indication
- 9.4.3. □RoW Eczema Therapeutics Market by Distribution Channel
- 9.4.4. □RoW Eczema Therapeutics Market by Sub-region
- 9.4.4.1. □Latin America Eczema Therapeutics Market
- 9.4.4.1.1. □Latin America Eczema Therapeutics Market by Drug Class
- 9.4.4.1.2. □Latin America Eczema Therapeutics Market by Disease Indication
- 9.4.4.1.3. □Latin America Eczema Therapeutics Market by Distribution Channel
- 9.4.4.2. □Middle East Eczema Therapeutics Market
- 9.4.4.2.1. □Middle East Eczema Therapeutics Market by Drug Class
- 9.4.4.2.2. □Middle East Eczema Therapeutics Market by Disease Indication
- 9.4.4.2.3. □Middle East Eczema Therapeutics Market by Distribution Channel
- 9.4.4.3. □Africa Eczema Therapeutics Market
- 9.4.4.3.1. □Africa Eczema Therapeutics Market by Drug Class
- 9.4.4.3.2. □Africa Eczema Therapeutics Market by Disease Indication
- 9.4.4.3.3. □Africa Eczema Therapeutics Market by Distribution Channel

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Eczema Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

Market Report | 2023-12-04 | 255 pages | Infinium Global Research and Consulting Solutions

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	1-5 User	\$4795.00
	Enterprise	\$7195.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input style="width: 95%;" type="text"/>	Phone*	<input style="width: 95%;" type="text"/>
First Name*	<input style="width: 95%;" type="text"/>	Last Name*	<input style="width: 95%;" type="text"/>
Job title*	<input style="width: 95%;" type="text"/>		
Company Name*	<input style="width: 95%;" type="text"/>	EU Vat / Tax ID / NIP number*	<input style="width: 95%;" type="text"/>
Address*	<input style="width: 95%;" type="text"/>	City*	<input style="width: 95%;" type="text"/>
Zip Code*	<input style="width: 95%;" type="text"/>	Country*	<input style="width: 95%;" type="text"/>
		Date	<input style="width: 95%;" type="text" value="2025-05-07"/>
		Signature	<div style="border: 1px solid black; height: 150px; width: 100%;"></div>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com